最好的期刊

E. Harnik, V. Harper, N. Patel
{"title":"最好的期刊","authors":"E. Harnik, V. Harper, N. Patel","doi":"10.1111/cea.13482","DOIUrl":null,"url":null,"abstract":"Yang TB et al. J Allergy Clin Immunol. 2019;144:353‐360 https ://doi.org/10.1016/j.jaci.2019.06.016 This is an exciting article addressing a common symptom of allergic disease(s)—itch. The authors discuss the currently understood im‐ muno‐pathogenesis and management of itch, highlighting how in‐ effective antihistamines are in combating itch, suggesting that the pathogenesis of itch encompasses both histaminergic (IgE‐mast cell‐ histamine axis) and non‐histaminergic pathways. Recent advances in the biology and neuroimmunology of itch have provided key new insight into the development of various new targeted therapies such as dupilumab, tralokinumab, lebrikizumab, neurokinin receptor an‐ tagonists, Mrgpr antagonists and JAK inhibitors, which are likely to transform the management of itch‐associated disorders in allergy and immunology.","PeriodicalId":10148,"journal":{"name":"Clinical & Experimental Allergy","volume":"34 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Best of the other journals\",\"authors\":\"E. Harnik, V. Harper, N. Patel\",\"doi\":\"10.1111/cea.13482\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Yang TB et al. J Allergy Clin Immunol. 2019;144:353‐360 https ://doi.org/10.1016/j.jaci.2019.06.016 This is an exciting article addressing a common symptom of allergic disease(s)—itch. The authors discuss the currently understood im‐ muno‐pathogenesis and management of itch, highlighting how in‐ effective antihistamines are in combating itch, suggesting that the pathogenesis of itch encompasses both histaminergic (IgE‐mast cell‐ histamine axis) and non‐histaminergic pathways. Recent advances in the biology and neuroimmunology of itch have provided key new insight into the development of various new targeted therapies such as dupilumab, tralokinumab, lebrikizumab, neurokinin receptor an‐ tagonists, Mrgpr antagonists and JAK inhibitors, which are likely to transform the management of itch‐associated disorders in allergy and immunology.\",\"PeriodicalId\":10148,\"journal\":{\"name\":\"Clinical & Experimental Allergy\",\"volume\":\"34 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Experimental Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1111/cea.13482\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Experimental Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/cea.13482","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

杨涛等。过敏临床免疫学杂志,2019;144:353‐360 https://doi.org/10.1016/j.jaci.2019.06.016这是一篇令人兴奋的文章,解决了过敏性疾病的常见症状-瘙痒。作者讨论了目前了解的瘙痒的免疫发病机制和管理,强调了抗组胺药如何有效地对抗瘙痒,表明瘙痒的发病机制包括组胺能(IgE -肥大细胞-组胺轴)和非组胺能途径。瘙痒生物学和神经免疫学的最新进展为开发各种新的靶向治疗提供了关键的新见解,如dupilumab, tralokinumab, lebrikizumab,神经激肽受体和拮抗剂,Mrgpr拮抗剂和JAK抑制剂,这可能会改变过敏和免疫学中瘙痒相关疾病的管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Best of the other journals
Yang TB et al. J Allergy Clin Immunol. 2019;144:353‐360 https ://doi.org/10.1016/j.jaci.2019.06.016 This is an exciting article addressing a common symptom of allergic disease(s)—itch. The authors discuss the currently understood im‐ muno‐pathogenesis and management of itch, highlighting how in‐ effective antihistamines are in combating itch, suggesting that the pathogenesis of itch encompasses both histaminergic (IgE‐mast cell‐ histamine axis) and non‐histaminergic pathways. Recent advances in the biology and neuroimmunology of itch have provided key new insight into the development of various new targeted therapies such as dupilumab, tralokinumab, lebrikizumab, neurokinin receptor an‐ tagonists, Mrgpr antagonists and JAK inhibitors, which are likely to transform the management of itch‐associated disorders in allergy and immunology.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信